Shared Instrumentation Grant

描述（由申请人提供）：申请资金用于为约翰霍普金斯大学购置一台真实的时间带电粒子放射自显影成像仪。该器械将辅助分子靶点检测（全身和组织分布、靶点特异性）、放射性配体开发（药代动力学和药理学特异性、与蛋白质表达的相关性）、放射性药物剂量测定（全身和组织剂量测定）。蛋白质调节、细胞增殖、组织代谢和血管形成的研究也将得到加强。选择了Biospace Measures Beta Imager 2000 Z带电粒子成像系统（2000 Z），因为它具有多种优势。它的大视野将允许全身放射自显影，其高灵敏度将允许H-3标记的配体成像。使用2000 Z正电子，β，α和电子与各种放射性示踪剂可以检测到在60至500微米的空间分辨率，在0.007 cpm/mm 2的检测阈值为3 H和效率高达90%。在104的动态范围内，成像器的线性度在2%以内。2000 Z成像仪可以同时检测两种或三种同位素，使用衰变时间差或带电粒子能量进行区分。多重标记开辟了新的应用，同时定量的几个分子目标的时间，这将支持药物和放射性配体的选择性研究。以列表模式收集数据，从而可以回顾性地检查在不同收集时间段内采集的图像。该设备可以实时显示收集的图像，从而消除曝光不足和过度曝光。相关性：2000 Z成像仪将定期由NIH资助的主要研究人员使用。每个项目都有强大的NIH资金，并与公共卫生有关。它们涵盖放射性药物和放射方法学的发展，以治疗癌症和诊断方法，以改善癌症和心血管疾病的检测。该仪器将对新放射性配体的开发以及PET和SPECT新定量算法的验证产生重大影响。它在基于β和α粒子辐射的放射性核素疗法的开发中也将是必不可少的，并且将显著影响配体和同位素的选择、递送方法、剂量测定的估计和治疗反应的测量。

DESCRIPTION (provided by applicant): Funds are requested for acquisition of a real time charged particle autoradiographic imager for the Johns Hopkins University. This device will assist molecular target detection (whole body and tissue distribution, target specificity), radioligand development (pharmacokinetics and pharmacological specificity, correlation with protein expression), radiopharmaceutical dosimetry (both whole body and tissue dosimetry). Investigations of protein regulation, cell proliferation, tissue metabolism and vascularization will also be enhanced. The Biospace Measures Beta Imager 2000Z charged particle imaging system (2000Z) has been selected because of its multiple advantages. Its large field of view will permit whole body autoradiography and its high sensitivity will permit imaging of H-3 labeled ligands. With the 2000Z positrons, betas, alphas and electrons associated with various radiotracers can be detected at spatial resolutions of 60 to 500 micrometer, at a detection threshold of 0.007 cpm/mm2 for 3H and with an efficiency as high as 90%. Linearity of the imager is within 2 % over the dynamic range of 104. The 2000Z Imager allows simultaneous detection of two or three isotopes using decay time differences or charged particle energies for discrimination. Multiple labeling opens up new applications with simultaneous quantification of several molecular targets at a time which will support drug and radioligand selectivity studies. Data are collected in list mode making it possible to retrospectively examine images acquired over different collection time-periods. The device can display the collected image in real-time, thereby eliminating under and over-exposures. RELEVANCE: The 2000Z Imager will be regularly employed by a major group of NIH funded researchers. Each of the included projects have strong NIH funding and are relevant to public health. They cover development of radiopharmaceuticals and radiation methodologies to treat cancer and diagnostic methods for improved detection of cancer and cardiovascular diseases. This instrument will have a strong impact on the development of new radioligands and for validation of new quantification algorithms for PET and SPECT. It will be also essential in the development of radionuclide therapies based on beta and alpha particle radiation and will significantly impact selection of ligands and isotopes, methods of delivery, estimation of dosimetry, and measurement of treatment response.